• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Applied Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/13/25 5:25:56 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLT alert in real time by email
    8-K
    false000169753200016975322025-05-132025-05-13

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 13, 2025

     

     

    Applied Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38898

    81-3405262

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    545 Fifth Avenue, Suite 1400

     

    New York, New York

     

    10017

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 212 220-9226

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001

     

    APLT

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

     


     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On May 13, 2025, Applied Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

     

     

    (d) Exhibits:

    The following exhibit is attached with this current report on Form 8-K:

    Exhibit
    No.

    Description

    99.1

    Press Release, dated May 13, 2025.

    104

    Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the inline XBRL document.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    APPLIED THERAPEUTICS, INC.
     

     

     

     

     

    Date:

    May 13, 2025

    By:

    /s/ Les Funtleyder

     

     

     

    Les Funtleyder, Interim Chief Executive Officer and Chief Financial Officer
     

     

     


    Get the next $APLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APLT

    DatePrice TargetRatingAnalyst
    12/23/2024Outperform → Mkt Perform
    William Blair
    12/2/2024$13.00 → $2.00Buy → Neutral
    UBS
    11/29/2024$12.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/31/2024Outperform
    William Blair
    3/26/2024$12.00Outperform
    RBC Capital Mkts
    2/22/2024$12.00Outperform
    Leerink Partners
    1/4/2022$44.00 → $7.00Overweight → Equal-Weight
    Barclays
    8/27/2021$10.00Neutral → Sell
    Goldman Sachs
    More analyst ratings

    $APLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

       Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study*) Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Treatment with govorestat in

      5/18/25 7:28:52 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Reports First Quarter 2025 Financial Results

      - Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting - Review of govorestat development programs for Classic Galactosemia and CMT-SORD Deficiency ongoing NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2025. "We continue to focus on executing against our operational, regulatory and clinical

      5/13/25 5:00:00 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

      NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that it will present full 12-month clinical results from the INSPIRE Phase 3 trial of govorestat (AT-007) in a late-breaking abstract selected for oral presentation at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20, 2025 in Edinburgh, Scotland. The presentation will also include new topline 18-month and 24-month data prior to the transition to the open-label extension study. The INSPIRE Phase 3 trial was a double-blind, placebo-controlle

      5/9/25 5:00:00 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

      SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

      11/14/24 5:47:55 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

      SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

      11/14/24 4:50:26 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

      SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

      11/14/24 4:38:38 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kanter Stacy J. bought $65,367 worth of shares (30,000 units at $2.18), increasing direct ownership by 91% to 63,000 units (SEC Form 4)

      4 - Applied Therapeutics Inc. (0001697532) (Issuer)

      12/5/23 7:03:09 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Hooks Corwin Dale was granted 250,000 shares, increasing direct ownership by 83% to 550,000 units (SEC Form 4)

      4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

      3/26/25 8:25:29 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Funtleyder Leslie D. was granted 350,000 shares, increasing direct ownership by 90% to 740,459 units (SEC Form 4)

      4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

      3/26/25 8:21:05 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Chinoporos Constantine was granted 350,000 shares, increasing direct ownership by 129% to 621,436 units (SEC Form 4)

      4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

      3/26/25 8:14:55 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Applied Therapeutics Inc.

      SCHEDULE 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

      5/15/25 4:30:28 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Applied Therapeutics, Inc. (0001697532) (Filer)

      5/13/25 5:25:56 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Applied Therapeutics Inc.

      SCHEDULE 13G - Applied Therapeutics, Inc. (0001697532) (Subject)

      4/30/25 10:54:07 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Applied Therapeutics downgraded by William Blair

      William Blair downgraded Applied Therapeutics from Outperform to Mkt Perform

      12/23/24 7:22:04 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics downgraded by UBS with a new price target

      UBS downgraded Applied Therapeutics from Buy to Neutral and set a new price target of $2.00 from $13.00 previously

      12/2/24 8:14:03 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Applied Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $12.00 previously

      11/29/24 7:22:55 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Financials

    Live finance-specific insights

    See more
    • Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

      Interim primary endpoint met; Statistically significant correlation of sorbitol with the CMT-FOM clinical outcome composite (p=0.05) Sustained, statistically significant reduction in sorbitol in govorestat-treated patients vs. placebo (p<0.001) Highly statistically significant effects on the CMT Health Index (CMT-HI) patient reported outcome measure (p=0.01), with benefit of govorestat on categories of lower limb function, mobility, fatigue, pain, sensory function, and upper limb function Company plans to request a pre-NDA meeting with the neurology division of the US FDA regarding potential approval based on current data Company to host investor conference call and webcast today at 8:3

      2/15/24 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission

      Govorestat demonstrated consistent long-term clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, confirming prior biomarker dataGovorestat treatment improved activities of daily living, behavior, cognition, fine motor skills, adaptive skills and tremor vs. placeboCompany plans to request a pre-NDA meeting with the FDA as soon as possible to discuss a potential NDA submission in second half of 2023; plans to submit a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in mid-2023  NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company

      4/24/23 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

      The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16-55 in the US and EuropeAT-007 reduced sorbitol by a mean of 52%, or approximately 16,000 ng/ml, over a 90 day period, which was highly statistically significant vs. placebo (p<0.001)Company to host conference call to discuss results at 8:30am Eastern NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medi

      2/16/23 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

      NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company's executive leadership team and will be responsible for leading Applied's global regulatory strategy. Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a diverse set of leadership roles over the course of his career, notably

      3/19/25 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

      NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmaceutical and medical device industries. In this newly created role, she will report directly to the executive leadership team and Executive Chairman, and will be responsible for overseeing all quality matters, including Good Manufacturing Practices, Good Laboratory Practices, and Good Clinical Practices. "We are pleased to

      1/21/25 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

      Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

      12/20/24 7:00:00 AM ET
      $APLT
      $RVPH
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care